Emcure Pharmaceuticals Limited (NSE:EMCURE)

India flag India · Delayed Price · Currency is INR
1,473.10
+2.40 (0.16%)
Feb 18, 2026, 10:30 AM IST
Market Cap278.80B +22.0%
Revenue (ttm)88.50B +17.2%
Net Income8.70B +43.2%
EPS45.90 +39.7%
Shares Out189.57M
PE Ratio32.04
Forward PE25.35
Dividend3.00 (0.20%)
Ex-Dividend Daten/a
Volume17,572
Average Volume150,741
Open1,471.80
Previous Close1,470.70
Day's Range1,461.70 - 1,492.20
52-Week Range889.00 - 1,585.60
Betan/a
RSI47.27
Earnings DateFeb 4, 2026

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the develop... [Read more]

Sector Healthcare
Founded 1981
Employees 6,731
Stock Exchange National Stock Exchange of India
Ticker Symbol EMCURE
Full Company Profile

Financial Performance

In fiscal year 2025, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.

Financial Statements